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Summary Background. The pattern of contact sensitization to the supposedly most important
allergens assembled in the baseline series differs between countries, presumably at least
partly because of exposure differences.
Objectives. To describe the prevalence of contact sensitization to allergens tested in
consecutive patients in the years 2007 and 2008, and to discuss possible differences.
Methods. Data from the 39 departments in 11 European countries comprising the
European Surveillance System on Contact Allergy network (www.essca-dc.org) in this
period have been pooled and analysed according to common standards.
Results. Patch test results with the European baseline series, and country-speciﬁc
or department-speciﬁc additions to it, obtained in 25 181 patients, showed marked
international variation. Metals and fragrances are still the most frequent allergens
across Europe. Some allergens tested nationally may be useful future additions to the
European baseline series, for example methylisothiazolinone, whereas a few long-term
components of the European baseline series, namely primin and clioquinol, no longer
warrant routine testing.
Conclusions. The present analysis points to ‘excess’ prevalences of speciﬁc contact
sensitization in some countries, although interpretation must be cautious if only
few, and possibly specialized, centres are representing one country. A comparison as
presented may help to target in-depth research into possible causes of ‘excess’ exposure,
and/or consideration of methodological issues, including modiﬁcations to the baseline
series.
Key words: clinical epidemiology; contact allergy; health reporting; patch testing.
The most important contact allergens are tradition-
ally assembled in a ‘baseline series’, which is usually
applied to every patient who is patch tested as a general
screening test. Recommendations regarding a European
baseline series are issued by the European Society of
Contact Dermatitis (www.escd.org) (1). National con-
tact dermatitis research groups often adopt these rec-
ommendations, usually with a number of omissions
and additions as deemed appropriate in the speciﬁc
country. Sometimes, a ‘monitor series’ is used, that
is, a temporary supplement to the baseline series to
quickly check whether certain allergens should pos-
sibly be included in the baseline series (2). Moreover,
singledepartmentsmaycompilesupplementstothebase-
line series to reﬂect local needs. Hence, some variation
of a seemingly standardized diagnostic tool is created,
offering the opportunity to evaluate possible changes
to national standard batteries or the European baseline
series.
In the present article, we summarize and discuss
results obtained with the European baseline series and
additions – all applied to consecutive patients – collected
by the members of the European Surveillance System on
Contact Allergy (ESSCA; www.essca-dc.org) network in
the years 2007 and 2008.
Methods
The ESSCA network has been described in previous
publications (3–5). Brieﬂy, clinical and demographic
data, along with patch test results, of all patients patch-
tested in the departments participating in the ESSCA
are documented electronically in the local departments,
with the use of diverse data capture software and, partly,
the multilingual software WINALLDAT/ESSCA provided by
the ESSCA (4). Patch testing follows international
recommendations (6), often reﬁned nationally. It is the
responsibility of national contact dermatitis groups,
if they exist in a country, to work on the quality
control and standardization of patch testing and to issue
recommendations regarding speciﬁc (additions to the)
baseline series. At 2-yearly intervals, data are transferred
to the Erlangen data centre. Standardized reports are
prepared and supplied to the network partners for a
critical review of the analyses. After possible corrections,
data are pooled for further analysis, with the use of SAS™
(version9.2;SASInstitute,Cary,NC,USA)and R(version
2.11.1; http://www.R-project.org) software.
For the present analyses, the maximum patch test
reactionbetweenday 3andday 5(inclusive)wasconsid-
ered as the outcome, with + to +++reactions classiﬁed
as positive, and negative, irritant and doubtful reactions
© 2012 John Wiley & Sons A/S
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Table 1. Characteristics of included countries and departments
comprising the European Surveillance System on Contact Allergy
network
No. of
departments
No. of
consultations
(cases)
No. (%) tested
with baseline
series
Austria 1 692 678 (98.0)
Denmark 1 1318 1318 (100)∗
Finland 2 760 760 (100)∗
Germany 6 3161 2712 (85.8)
Italy 3 (4†) 3052 2938 (96.3)
Lithuania 1 680 680 (100)
The Netherlands 2 2325 2172 (93.4)
Poland 3 936 793 (84.7)
Spain 5 2018 1845 (91.4)
Switzerland 3 2586 2415 (93.4)
United Kingdom 12 9201 9201 (100)∗
∗Onlydataofpatientstestedwithbaselineserieswereregisteredand
submitted.
†‘Padova Pediatrica’ not included in this particular analysis, owing
to an entirely paediatric population.
as non-positive. In cases of multiple consultations, with
multiple applications of the baseline series within this 2-
year period, the strongest patch test reaction per patient
was chosen. It should be noted that only the results of
the current patch test session were considered in our
analysis; that is, patients not tested with a particular
allergen,becauseofknownsensitization,arenotcounted
as positive. Depending on the role of a department in the
national healthcare framework, the proportion of such
‘prediagnosed’ patients may be non-negligible, and thus
leadtoanunderestimationofthetruesensitizationpreva-
lence in these departments. Sensitization frequencies are
given directly as age-standardized and sex-standardized
prevalences (7), accompanied by a 95% conﬁdence inter-
val (CI). This allows comparisons to be made that are not
confounded by age and sex. We have chosen the country
as the unit of aggregation of results in this analysis.
Results
Data from 39 departments in 11 European countries
are included; for more details, see Table 1. During the
2-year study period (January 2007 to December 2008),
26 729consultations,yielding25 512applicationsofthe
baseline series, by 25 181 patients were documented.
The demographic and clinical characteristics accord-
ing to the MOAHLFAP index (8) in the countries are
shown in Table 2. With the exception of Lithuania, the
proportion of male patients is in a fairly narrow range
of 32–40%, whereas other characteristics differ more,
in particular age or face dermatitis, mostly indicative of
cosmetic contact allergy. Characteristics seem to vary
more between departments within one country than
between countries, as judged by averages.
The practice of patch testing across Europe with the
European baseline series is evident from Table 1 (regard-
ing the proportion of patients tested with the European
baseline series) and from Table 3 (regarding the scope
of allergens). In some cases, allergens recommended for
the European baseline series (1) had not been included
in certain countries, for example clioquinol. Some aller-
gens were not tested as recommended; for example, the
mercapto mix (1% pet.) without mercaptobenzothiazole
(MBT) was used by most departments instead of the mer-
captomixincludingMBT(2%pet.).Thetwocorticosteroid
screening agents, tixocortol pivalate and budesonide,
were tested at 1% and 0.1%, respectively, in several
countries, instead of at the recommended concentrations
of 0.1% and 0.01%.
Regarding the results, for the sake of compactness
the number of patients tested with the European baseline
seriesisgivenonlyonce,intheﬁrstrow,eventhoughsome
deviations from this number may have occurred – these
are noted only if the number of patients tested with an
allergen is <90% of this overall number. The number
and crude percentage of positive reactions are not
shown; only the age-standardized and sex-standardized
proportions are given (for reasons of space limitation).
The use of standardized prevalences is justiﬁed by the
considerable differences in the age structure, if sex is not
regarded, of patch-tested patients in our clinical sample.
Sensitization prevalences in the countries are, to some
extent, inﬂuenced by the background of departments
in those countries where few centres participate. For
instance, the background of an interest in occupational
dermatitis introduces a bias for Finland, with the
Finnish Institute of Occupational Health as one of two
departments, and for Poland, with the Nofer Institute as
one of three departments (Table 2). For just one allergen,
sensitization prevalence varies by a factor of 2, namely,
p-phenylenediamine. For all other allergens, including
those for which an occupational background is not
prominent, for example nickel, cobalt, neomycin sulfate,
and the fragrance screening allergens, considerable, and
often signiﬁcant (if 95% CIs do not overlap), differences
betweensensitizationfrequenciesareseenoncomparison
of different countries.
The proportions of patients who reacted to at least
one of the preservatives included in the European
baseline series (Table 3) were 5.0% for the UK, 5.6%
for Switzerland, 6–8% for most countries, 9.5% for
Finland, 9.9% for Austria, and 12.9% for Lithuania.
Cross-tabulation of results with formaldehyde versus
© 2012 John Wiley & Sons A/S
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Table 2. MOAHLFAP index (8) of patients patch-tested in 11 European countries: average % (range; where appropriate)
MOAH L FA P
Austria 34 16 17 24 9 14 66 54
Denmark 33 24 19 43 3 23 63 40
Finland 38 (32–48) 39∗ (26–61) 27 (22–30) 51 (38–72) 3 (1–5) 15 (14–15) 61 (55–65) 50 (43–54)
Germany 39 (35–49) 22 (14–29) 16 (10–23) 31 (22–37) 8 (6–12) 17 (9–25) 70 (62–78) 43 (32–49)
Italy 34 (31–37) 10 (6–15) 10 (5–15) 27 (26–31) 9 (7–11) 17 (15–19) 51 (49–54) 46 (42–53)
Lithuania 26 21 17 32 9 34 62 47
The Netherlands 36 (36–36) 22 (21–24) 27 (25–30) 24 (21–30) 5 (4–5) 21 (17–26) 56 (53–58) 47 (40–52)
Poland 32 (30–36) 28 (24–29) 18 (8–24) 40 (34–43) 4 (2–7) 15 (13–19) 48 (16–67) 45 n(31–76)
Spain 35 (31–40) 16 (5–57) 11 (7–27) 26 (17–66) 9 (1–12) 14 (4–24) 64 (45–76) 49 (48–51)
Switzerland 40 (38–44) 17 (16–19) 17 (10–27) 31 (21–37) 7 (5–8) 17 (15–20) 62 (60–63) 48 (42–54)
United Kingdom 33 (27–39) 11 (8–18) † 30 (24–43) 7 (5–9) 28 (22–31) 57 (51–64) 43 (33–60)
M, male; O, occupational; A, age ≥ 40 years; H, hand; L, leg; F, face; A, atopic dermatitis; P, percentage of patients positive to at least one
allergen of the baseline series.
∗Comprising predominant and exclusive occupational causation.
†Atopy in general recorded, that is, also comprising history of allergic rhinitis and asthma.
diazolidinylureain9950(imidazolidinylureain11 531)
patients tested with both respective allergens identiﬁed
a proportion of 53% (58%) patients positive to these
formaldehyde-releasers without a concomitant positive
reaction to formaldehyde.
Table 4 lists a number of allergens that have been
tested in addition to the European baseline series, that is,
in consecutive patients, so that sensitization prevalences
are comparable to those obtained with the original
European baseline series (Table 3), in more than two
countries. The two formaldehyde-releasers diazolidinyl
ureaandimidazolidinylureaarerelativelyrareallergens,
with a sensitization prevalence of up to 1%, except for
Finland, where a higher prevalence is noted. 2-Bromo-2-
nitropropane-1,3-diol [bronopol (INN)], which has been
testedatboth0.5%pet.and0.25%pet.,isaslightlymore
frequentallergen.Commentsonotherallergensaregiven
in the discussion.
Discussion
Continual analysis of prevalences of sensitization to
the most important allergens–in terms of frequency
of sensitization in patients patch-tested, as provided
by these current results from the ESSCA–is important
for a number of reasons: (i) detection of temporal
trends or geographical differences (which could indicate
exposurechangesordifferencesneedingtobeinvestigated
or prompting intervention, as appropriate); (ii) as a
contribution to standardized, comparative international
health reporting; and (iii) as a quality control measure
regarding the diagnostic usefulness of the battery of
screening allergens used. However, despite all efforts
at standardization, methodological variation must also
be discussed as a potential source of variation between
countries and even between departments within one
country. In the following discussion, we will address
these aspects, as appropriate, in subsections deﬁned by
categories of allergens.
Metals
Nickel is still the by far most common allergen, although
there is a greater than two-fold variation between
countries. The low frequency observed in Denmark
is probably attributable to the longstanding nickel
regulation established there, which has shown a marked
beneﬁcial effect before (9). Conversely, persistently high
prevalences in other countries may indicate later
implementationoftheregulation,differentfashionhabits,
or insufﬁcient control of exposure (10–12). The partial
beneﬁcial effect of the EU nickel regulation has recently
been reviewed (11); the very recent tightening of a
‘tolerance factor’ for the measurement of nickel release
according to EN 1811 (13) is expected to contribute to a
further reduction in nickel exposure and sensitization in
thefuture.However,beyondnickel,averyhighfrequency
of cobalt contact sensitization is observed, at >5% in all
included countries, and particularly high prevalences
are seen in countries where occupational dermatology
departmentshaveanimpact,namelyFinlandandPoland,
but also in Graz, Austria and in Switzerland. This is in
line with the observation of cobalt being the second most
common allergen in the ﬁrst ESSCA analysis, covering
the years 2002 and 2003 (14). Often, exposure to cobalt
remains unclear in patients with cobalt sensitization; the
question of whether individual ‘metal contacts’ could
possibly cause allergic contact dermatitis can, in the
future, be addressed by the use of a recently available
© 2012 John Wiley & Sons A/S
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spottestforcobalt (15).Ithasbeenspeculatedthatcobalt
has replaced nickel in cheap jewellery (16), which may
contribute to the observed high sensitization frequency.
Regarding chromium, the third metal included in the
European baseline series, no clear geographical pattern
can be observed. Following the EU-wide regulation of the
content of hexavalent chromium in cement1, a similar
decrease in the incidence of occupational chromium
sensitization caused by cement exposure, as seen decades
before in Scandinavia, has recently been observed,
for instance, in Germany (17). At present, chromium
exposure via leather seems to be gaining importance as
a cause of sensitization (18). False-positive patch test
reactions to metal salts are not entirely uncommon,
according to the work of Fischer and Rystedt (19),
and may thus, to some extent, bias the sensitization
prevalencesupwards,especiallyforcobaltandchromium.
Fragrances
The prevalence of sensitization to fragrance mix (FM)
I is lowest in the southern countries (Italy and Spain)
and Lithuania, and highest in western and central
Europe. This pattern is not paralleled by sensitization
to Myroxylon pereirae resin (balsam of Peru), which,
in a few countries, even exceeds that to FM I. The
newer FM II is also an important screening allergen,
although nowhere exceeding FM I. It has been stressed
that only extracts or distillates of M. pereirae are used
in perfumery (20); however, exposure to these, or to
some of the single constituents, is apparently so intense
or frequent that this oldest of fragrance contact allergy
screening allergens is still important. Hydroxyisohexyl
3-cyclohexenecarboxaldehyde,themostimportantsingle
substancefromFMII,isarelativelyfrequentallergenand
is justiﬁably part of the European baseline series (1).
Preservatives (biocides)
Parabens are not frequent allergens and, considering the
vastamountofexposure,areassociatedwithalowriskof
sensitization (21). Interestingly, sensitization prevalence
is highest in the two eastern countries and Austria (the
Austrian centre having high sensitization prevalences
throughout,possiblybecauseofahighlyselectedgroupof
patients;seealsothehighestPmeasureinTable 2).Preva-
lences of sensitization to formaldehyde vary greatly, and
are highest in Finland and Poland, most likely because
of the occupational background of the two respective
1 DIRECTIVE 2003/53/EC OF THE EUROPEAN PARLIAMENT
AND OF THE COUNCIL of 18 June 2003 http://eur-lex.europa.
eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:178:002
4:0027:en:PDF
departments, with a number of cases with occupational
exposure to formaldehyde. Quaternium-15 has a sensiti-
zation prevalence of 1% (or well above), with more lim-
ited variation. Exposure to methylchloroisothiazolinone
(MCI)/methylisothiazolinone(MI)3:1,awell-knowncon-
tactsensitizer,hasbeenpartiallyregulated,themaximum
concentration in cosmetic products being 15 ppm (22).
However, sensitization prevalences remain quite stable
at 1–4%, and slightly above. The question also remains
of whether the recent increased use of MI (permitted at
up to 100 ppm in cosmetics (23), but otherwise unregu-
lated) (24)ispossiblycontributingtoapersistingproblem
with MCI/MI (25). One of the successors of MCI/MI is
methyldibromo glutaronitrile (MDBGN). This has turned
out to be an important contact sensitizer in humans, as
shown by a remarkable epidemic of contact sensitization
across Europe soon after its use expanded massively. In
keepingwiththis,ﬁguresarehighforMDBGN,whichhas
been tested at 0.2–0.5% (Table 3). However, following
the banning of MDBGN, ﬁrst in leave-on and later also
in rinse-off products, prevalences are expected to fall, and
have indeed begun to do so according to some recent
national surveillance data (26, 27).
A number of other preservatives have been tested
in consecutive patients, in addition to, or as part of,
adapted baseline series (Table 4). Approximately 1%
of patients were found to be sensitized to diazolidinyl
urea and imidazolidinyl urea, respectively, with the
highest proportions being observed in Finland. Thus,
these are ‘borderline candidates’ for possible inclusion
in a baseline series (in those countries where they
are not yet included). Interestingly, and in contrast to
previous results (27, 28), more than half of the patients
sensitized to the above formaldehyde-releasers did not
show concomitant sensitization to formaldehyde. The
prevalence of sensitization to 2-bromo-2-nitropropane-
1,3-diolisquiteclearlyabove1%infourcountries,butnot
in Lithuania. The small size of the Lithuanian subsample
does not rule out the existence of a relevant sensitization
frequency there (upper 95% conﬁdence limit: 2.3%). The
signiﬁcanceofiodopropynylbutylcarbamate,incontrast,
has yet to be settled.
Topical drugs
Neomycin sulfate has been part of various baseline series
for a long time. However, according to the prevalences
seen in different countries, its importance may differ
according to whether it is available by prescription
only or ‘over the counter’. In central Europe, expo-
sureandsensitizationprevalencehavebeencontinuously
decreasing (29),promptingtheGermanContactDermati-
tis Group to remove it from the German baseline series.
© 2012 John Wiley & Sons A/S
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However, in other countries, it may be well warranted to
testthisaminoglycosideroutinely.Similarconsiderations
are valid for benzocaine (or caine mix III, as tested by the
British Society for Cutaneous Allergy), which seems to be
aworthwhilepartofthebaselineseriesinsomecountries.
Incontrast,clioquinolisarareallergen;infact,theupper
95%conﬁdencelimitis≤1%inthosecountriesstilltesting
it. Thus, clioquinol signiﬁcantly fails to meet the conven-
tional criterion for inclusion in the baseline series (30).
For several years, budesonide and tixocortol pivalate (the
latterasamarkerforhydrocortisonecontactallergy)have
been part of the recommended European baseline series.
The sensitization prevalences observed in this analysis
give borderline justiﬁcation for this. Bufexamac (Table 4)
was part of the baseline series in some countries where
it was used; however, thanks to a recent revocation
of marketing authorization by the European Medicines
Agency (31), based on a negative assessment of the bal-
ance of effectiveness (not proven) and adverse effects
(contact sensitization: well proven!), contact allergy to
bufexamac should become a thing of the past.
Rubber additives
The pattern of nationally aggregated prevalences of
sensitization to thiuram mix is peculiar, as in eight
countries this lies in a narrow range between 2.0 and
2.7%, whereas in Italy, Lithuania and The Netherlands,
it is considerably lower. Neither this pattern, nor the
reverse, is reﬂected in the prevalence of sensitization
to mercaptobenzothiazole or mercapto mix. Thus, our
morbidity data cannot provide a simple explanation
in terms of more exposure to benzothiazoles and
less exposure to thiurams/dithiocarbamates. This issue
should be addressed by appropriate ﬁeld studies. In some
countries, ‘black rubber mixes’ are partly used instead
of N-isopropyl-N -phenyl-p-phenylenediamine (IPPD).
IPPD itself is an uncommon allergen, with sensitization
prevalences ranging from well below 1% to ∼ 1%.
Sometimes, a ‘carba mix’ is tested in baseline series;
in other cases, zinc diethyldithiocarbamate is tested as
onerepresentativeofthisclassofvulcanizingagents.This
is not a frequent allergen; however, cross-reactivity to
theantigenically closelyrelatedthiurams/thiurammixis
very prominent (32).
Miscellaneous agents
p-Phenylenediamine is an important contact aller-
gen (33),sensitizationbeingrelatedtohairdyeexposure,
whichmaybeoccupationalin∼ 50%ofcases (34).Lano-
lin (wool alcohols) is a controversial allergen. In the
present analysis, ≥1% positive patch test reactions were
noted in most of the countries; however, the clinical rel-
evance, particularly of weak positive reactions, is often
difﬁcult to establish or verify by the use of patch tests
or repeated open application tests. Cetearyl (cetostearyl)
alcohol, in contrast, evoked positive patch test reactions
in ≤1% of cases, and is thus a borderline component
of baseline series. Epoxy resins [bisphenol A diglycidyl
ether (BADGE)] are predominantly occupational aller-
gens, with increasing importance, for instance in the
building trade (17). However, the BADGE type used in
the European baseline series detects most, but not all,
casesofsensitizationtoepoxysystemcomponents.p-tert-
Butylphenol formaldehyde resin is a glue that is mostly
used for shoes, and is thus one of the most important
‘shoe allergens’, with a relatively low general sensitiza-
tion prevalence. The sesquiterpene lactone mix elicited
positive patch test reactions in <1% of cases in those
countries testing it; the frequencies of sensitization to dif-
ferent Compositae mixes aimed at also covering allergens
beyond the three most important sesquiterpene lactones
included in the sesquiterpene lactone mix were in a sim-
ilar range. Primin has repeatedly been found to be an
unimportant allergen, except possibly in special regional
situations (3,5,14);itsexclusionfromtheEuropeanbase-
line series should be discussed (35). Oil of turpentine is
sometimes regarded as a ‘historical’ allergen, as its main
useasasolventforpaintsandrelatedproductshasmostly
been abandoned, except in ‘alternative’ or ‘natural’ types
of product. However, it is a fairly important sensitizer in
those countries where it is tested routinely. The tempo-
ral trend previously paralleled that of FM I, suggesting
that it may be a marker of sensitization to (oxidized)
terpenes used in perfumery (36). Propolis is used, with
strong regional differences, in ‘alternative’ or ‘natural’
topical products, foodstuffs, or folk remedies of various
kinds. This natural mixture contains a number of sensi-
tizingsubstances.Theuseofpropolisinthebaselineseries
hasbeenrecommended (37).DisperseBlue106/124was
labelled as ‘allergen of the year’ in 2000. However, at
present, prominent prevalence on screening testing is
noted only in Italy, whereas Finland and the UK the
prevalenceislow.Colophonium(colophony)isacomplex
mixture of over 100 compounds derived from Pinaceae,
with a highly variable content, moreover, spontaneous
oxidation and industrial processing of colophony may
result in the formation of new sensitizers. Contact sensi-
tization to colophonium tested in the European baseline
seriesisnotuncommon;sourcesofexposureincludeoccu-
pational (cutting ﬂuids, wood from conifers, and adhe-
sives) and non-occupational (adhesives and cosmetics)
products.
© 2012 John Wiley & Sons A/S
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Conclusion
The pooled analysis of European patch test data shows
international variation in sensitization prevalences. This
is most likely attributable to differences in exposure, at
least to a certain extent. A number of allergens have
been identiﬁed that are not deemed to be a necessary
part of a European baseline series (e.g. primin and
clioquinol), whereas other allergens with some impor-
tanceinthecountriestestingthemroutinelymaywarrant
considerationforinclusionintheEuropeanbaselineseries
(particularly MI, and possibly oil of turpentine). Contin-
uedsurveillanceisneededtomonitordevelopingallergens
across Europe.
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